Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): A randomized controlled study

Prostate Cancer and Prostatic Diseases

Volumn 8, Issue 3, 2005, Pages 215-218

  Özdal, Ö Levent ^a,b   Ozden C ^a   Benli, K ^a   Gokkaya S ^a   Bulut, S ^a   Memis A ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

BPH; Finasteride; Peroperative bleeding; TUR P

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; FINASTERIDE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; DRUG EFFECT; DRUG EFFICACY; ERECTILE DYSFUNCTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPOTENCE; LAVAGE; LIBIDO DISORDER; OPERATION DURATION; PATIENT SELECTION; PEROPERATIVE COMPLICATION; PREMEDICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; TRANSURETHRAL RESECTION;

AGE FACTORS; AGED; ANTICOAGULANTS; ASPIRIN; FINASTERIDE; HEMOGLOBINS; HUMANS; KIDNEY FAILURE; MALE; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK; TIME FACTORS; TRANSURETHRAL RESECTION OF PROSTATE; URETHRA; WARFARIN;

EID: 31044455913     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500818     Document Type: Article

References (24)

1. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: Immediate and postoperative complications. A cooperative study of 13 participating institutions evaluation of 3885 patients. J Urol 1989; 141: 243-247.
2. Melchior J, Valk WL, Foret JD, Mebust WK. Transurethral prostatectomy: computerized analysis of 2223 consecutive cases. J Urol 1974; 112: 634-642.
3. Lissbrant IF, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 1998; 139: 451-456.
4. Lekas E et al. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res 1997; 25: 309-314.
5. Shabsigh A et al. Rapid reduction in blood flow to the rat ventral prostate after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998; 36: 201-216.
6. Carlin BI, Bodner DR, Spinnak JP, Resnick MI. Role of finasteride in the treatment of hematuria secondary to benign prostatic hyperplasia. Prostate 1997; 31: 180-182.
7. Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: A preliminary report. J Urol 1995; 154: 1779-1782.
8. Sieber PR et al. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 1998; 159: 1232-1233.
9. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997; 3: 2507-2511.
10. Haggstrom S, Lissbrant IF, Bergh A, Damber JE. Testosterone induces vascular endothelial growth factor synthesis in the ventral prostate in castrated rats. J Urol 1999; 161: 1620-1625.
11. Bailey DM, Foley SJ. Microvascular anatomy in patients with recurrent hematuria related to prostatic hypertrophy (BPH). J Urol 1999; 161: 865 (abstract).
12. Levine AC et al. Androgens induce the expression of the vascular endothelial growth factors in human fetal prostatic fibroblasts. Endocrinology 1998; 139: 4672-4678.
13. Kashif KM, Foley SJ, Basketter V, Holmes SA. Haematuria associated with BPH-Natural history and a new treatment option. Prostate Cancer Prostatic Dis 1998; 1: 154-156.
14. Ekengren J, Hahn RG. Blood loss during transurethral resection of the prostate as measured by the hemocue photometer. Scand J Urol 1993; 27: 501-517.
15. Gormley GJ et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 1992; 327: 1185-1191.
16. Stoner E. The clinical effects of 5α-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group. J Urol 1992; 147: 1298-1302.
17. Saez C et al. Expression of basic fibroblast growth factors and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate 1999; 40: 83-88.
18. Monti S et al. Prevalent decrease of the EGF content in the periurethral zone of BPH tissue induced by the treatment with finasteride or flutamide. J Androl 1997; 18: 488-494.
19. Schwartz Jr S et al. Androgen-independent basal cell re-epithelialization, c-erbB-2 mRNA expression and androgen-dependant EGFr mRNA expression in benign prostatic hyperplasia explant cultures treated with finasteride. Int J Cancer 1998; 76: 519-522.
20. Moon S-Y, Moon W-C, Choi HR, Gi Y-J. Finasteride inhibits angiogenesis and expression of VEGF in human BPH. J Urol 1998; 159: 332 (abstract).
21. Bailey DM, Foley SJ, Wedderburn A. effect of finasteride on microvessel density (MVD) in patients with recurrent haematuria related to prostatic hypertrophy (BPH). J Urol (suppl) 1999; (abstract).
22. Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethral resection of the prostate. Urology 2000; 55: 684-689.
23. Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 2001; 58: 972-976.
24. Donohue JF et al. Transurethral resection and bleeding: A randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 2002; 168: 2024-2026.